David M. Cross

1.3k total citations
18 papers, 385 citations indexed

About

David M. Cross is a scholar working on Molecular Biology, Pharmacology and Small Animals. According to data from OpenAlex, David M. Cross has authored 18 papers receiving a total of 385 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Pharmacology and 4 papers in Small Animals. Recurrent topics in David M. Cross's work include Neuroscience and Neuropharmacology Research (4 papers), Receptor Mechanisms and Signaling (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). David M. Cross is often cited by papers focused on Neuroscience and Neuropharmacology Research (4 papers), Receptor Mechanisms and Signaling (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). David M. Cross collaborates with scholars based in United Kingdom, United States and Netherlands. David M. Cross's co-authors include Martin K. Bayliss, Neil T. Thompson, Nicola G. Wallis, Ruth E. Feltell, John F. Lyons, Edward J. Lewis, Matthew Squires, Donna-Michelle Smith, R.B. Kemp and Elizabeth Horsley and has published in prestigious journals such as Food and Chemical Toxicology, Molecular Cancer Therapeutics and British Journal of Clinical Pharmacology.

In The Last Decade

David M. Cross

18 papers receiving 373 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David M. Cross United Kingdom 10 182 126 78 49 41 18 385
William Neway United States 11 264 1.5× 203 1.6× 26 0.3× 98 2.0× 27 0.7× 14 557
Joseph Jamieson United States 5 308 1.7× 104 0.8× 35 0.4× 81 1.7× 12 0.3× 6 545
Giuseppina Gangemi Italy 4 119 0.7× 64 0.5× 76 1.0× 20 0.4× 19 0.5× 4 448
Cory Iverson United States 8 394 2.2× 85 0.7× 39 0.5× 21 0.4× 53 1.3× 15 599
F.W. Birke Germany 9 156 0.9× 52 0.4× 32 0.4× 43 0.9× 14 0.3× 15 343
Xiaomeng Shen United States 18 462 2.5× 96 0.8× 79 1.0× 28 0.6× 48 1.2× 31 754
Bryan D. Marks United States 13 244 1.3× 83 0.7× 29 0.4× 138 2.8× 15 0.4× 17 442
Junko Ushiki Japan 10 161 0.9× 325 2.6× 35 0.4× 73 1.5× 18 0.4× 14 564
Vladimir Piotrovsky United States 9 199 1.1× 170 1.3× 44 0.6× 45 0.9× 7 0.2× 12 470
Prasad Kopparapu United States 8 141 0.8× 93 0.7× 32 0.4× 22 0.4× 11 0.3× 11 330

Countries citing papers authored by David M. Cross

Since Specialization
Citations

This map shows the geographic impact of David M. Cross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Cross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Cross more than expected).

Fields of papers citing papers by David M. Cross

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Cross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Cross. The network helps show where David M. Cross may publish in the future.

Co-authorship network of co-authors of David M. Cross

This figure shows the co-authorship network connecting the top 25 collaborators of David M. Cross. A scholar is included among the top collaborators of David M. Cross based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David M. Cross. David M. Cross is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Nathan, Pradeep J., A. Godwood, Odile Dewit, et al.. (2022). A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M 1 receptor agonist HTL0018318 in patients with mild‐to‐moderate Alzheimer's disease. Alzheimer s & Dementia Translational Research & Clinical Interventions. 8(1). e12273–e12273. 5 indexed citations
2.
Bakker, C. J. G., Jasper van der Aart, Geert Labots, et al.. (2021). Safety and Pharmacokinetics of HTL0018318, a Novel M1 Receptor Agonist, Given in Combination with Donepezil at Steady State: A Randomized Trial in Healthy Elderly Subjects. Drugs in R&D. 21(3). 295–304. 5 indexed citations
3.
Bakker, C. J. G., Tim Tasker, Ellen P. Hart, et al.. (2021). Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study. Alzheimer s Research & Therapy. 13(1). 87–87. 13 indexed citations
4.
Bakker, C. J. G., Ellen P. Hart, Erica S. Klaassen, et al.. (2021). Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M1‐acetylcholine receptor agonist: A randomized cross‐over trial. British Journal of Clinical Pharmacology. 87(11). 4439–4449. 3 indexed citations
5.
Bakker, C. J. G., Tim Tasker, Ellen P. Hart, et al.. (2020). First‐in‐man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M1‐receptor partial agonist for the treatment of dementias. British Journal of Clinical Pharmacology. 87(7). 2945–2955. 13 indexed citations
6.
Cross, David M., Gary W. Chmielewski, Elise Lewis, et al.. (2012). Non-clinical safety assessment and toxicokinetics of voriconazole and anidulafungin in the juvenile rat: A combination study design in support of a Paediatric Investigation Plan. Regulatory Toxicology and Pharmacology. 63(1). 29–39. 3 indexed citations
7.
8.
9.
Cross, David M., et al.. (2012). An Evaluation of Reproductive and Developmental Toxicity of Sitaxentan (Thelin) in Rats. Birth Defects Research Part B Developmental and Reproductive Toxicology. 95(5). 327–336. 10 indexed citations
10.
Ripp, Sharon L., Jalal A. Aram, Christopher Bowman, et al.. (2012). Tissue Distribution of Anidulafungin in Neonatal Rats. Birth Defects Research Part B Developmental and Reproductive Toxicology. 95(1). 89–94. 10 indexed citations
11.
Bowman, Christopher, et al.. (2011). Juvenile toxicity assessment of anidulafungin in rats: an example of navigating case-by-case study design through scientific and regulatory challenges. Birth Defects Research Part B Developmental and Reproductive Toxicology. 92(4). n/a–n/a. 6 indexed citations
12.
Graham, Brent, Jayne Curry, Tomoko Smyth, et al.. (2011). The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non‐small cell lung cancer. Cancer Science. 103(3). 522–527. 65 indexed citations
13.
Squires, Matthew, Ruth E. Feltell, Nicola G. Wallis, et al.. (2009). Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Molecular Cancer Therapeutics. 8(2). 324–332. 134 indexed citations
14.
Cross, David M. & Martin K. Bayliss. (2000). A COMMENTARY ON THE USE OF HEPATOCYTES IN DRUG METABOLISM STUDIES DURING DRUG DISCOVERY AND DEVELOPMENT*. Drug Metabolism Reviews. 32(2). 219–240. 56 indexed citations
15.
Cross, David M., et al.. (1995). Kinetics of ranitidine metabolism in dog and rat isolated hepatocytes. Xenobiotica. 25(4). 367–375. 6 indexed citations
16.
Cross, David M., Keith Wilson, & John Bell. (1990). Enzymology of ranitidine metabolism in isolated hepatocytes from dog. Biochemical Society Transactions. 18(6). 1199–1200. 1 indexed citations
17.
Kemp, R.B., et al.. (1988). Comparison of cell death and adenosine triphosphate content as indicators of acute toxicity in vitro. Xenobiotica. 18(6). 633–639. 9 indexed citations
18.
Kemp, R.B., et al.. (1986). Adenosine triphosphate as an indicator of cellular toxicity In vitro. Food and Chemical Toxicology. 24(6-7). 465–466. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by William Neway Breakdown of academic impact, for papers by Joseph Jamieson Breakdown of academic impact, for papers by Giuseppina Gangemi Breakdown of academic impact, for papers by Cory Iverson Breakdown of academic impact, for papers by F.W. Birke Breakdown of academic impact, for papers by Xiaomeng Shen Breakdown of academic impact, for papers by Bryan D. Marks Breakdown of academic impact, for papers by Junko Ushiki Breakdown of academic impact, for papers by Vladimir Piotrovsky Breakdown of academic impact, for papers by Prasad Kopparapu
Rankless by CCL
2026